Eli Lilly, based in Indianapolis, has raised its annual profit and revenue forecasts after reporting a strong first quarter, primarily driven by the demand for its GLP-1 drugs, Zepbound and Mounjaro. The company now expects adjusted earnings of $35.50 to $37.00 per share for the year, an increase from a prior estimate of $33.50 to $35.00. This adjustment comes after Lilly reported an adjusted profit of $8.55 per share, significantly higher than the anticipated $6.66. Sales for Mounjaro reached $8.7 billion, surpassing expectations by more than $1 billion, while Zepbound contributed $4.2 billion in sales for the quarter, also exceeding estimates. CEO David Ricks expressed optimism about the strong start to 2026 and the potential of Foundayo, Lilly's recently launched oral obesity drug, to expand the market for GLP-1 treatments. However, the rollout of Foundayo has seen only 3,707 prescriptions in its first week, falling short of analysts' expectations of around 8,000. As competition intensifies with rival Novo Nordisk, which launched Wegovy first, investors are keenly observing Lilly's ability to capture market share in the growing GLP-1 drug market, projected to exceed $150 billion in revenue over the next decade.